These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 32883678)

  • 1. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.
    Chen LYC; Hoiland RL; Stukas S; Wellington CL; Sekhon MS
    Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32883678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Audio Interview: Tocilizumab and Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 Oct; 383(17):e114. PubMed ID: 33085870
    [No Abstract]   [Full Text] [Related]  

  • 3. COVID-19: Some clinical questions after the first 4 months.
    Bassetti M; Ansaldi F; Icardi G; Pelosi P; Robba C; Taramasso L; Trucchi C; Vena A; Giacobbe DR
    Eur J Clin Invest; 2020 Jul; 50(7):e13326. PubMed ID: 32562550
    [No Abstract]   [Full Text] [Related]  

  • 4. The COVID-19 Cytokine Storm; What We Know So Far.
    Ragab D; Salah Eldin H; Taeimah M; Khattab R; Salem R
    Front Immunol; 2020; 11():1446. PubMed ID: 32612617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-6 and severe COVID-19: a systematic review and meta-analysis.
    Mojtabavi H; Saghazadeh A; Rezaei N
    Eur Cytokine Netw; 2020 Jun; 31(2):44-49. PubMed ID: 32933891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
    Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
    J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting inflammation and cytokine storm in COVID-19.
    Huang Q; Wu X; Zheng X; Luo S; Xu S; Weng J
    Pharmacol Res; 2020 Sep; 159():105051. PubMed ID: 32603772
    [No Abstract]   [Full Text] [Related]  

  • 8. Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.
    Hoiland RL; Stukas S; Cooper J; Thiara S; Chen LYC; Biggs CM; Hay K; Lee AYY; Shojania K; Abdulla A; Wellington CL; Sekhon MS
    Br J Haematol; 2020 Aug; 190(3):e150-e154. PubMed ID: 32584416
    [No Abstract]   [Full Text] [Related]  

  • 9. IL-6: Relevance for immunopathology of SARS-CoV-2.
    Gubernatorova EO; Gorshkova EA; Polinova AI; Drutskaya MS
    Cytokine Growth Factor Rev; 2020 Jun; 53():13-24. PubMed ID: 32475759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. After 62 years of regulating immunity, dexamethasone meets COVID-19.
    Cain DW; Cidlowski JA
    Nat Rev Immunol; 2020 Oct; 20(10):587-588. PubMed ID: 32778829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.
    Abdulrab S; Al-Maweri S; Halboub E
    Med Hypotheses; 2020 Oct; 143():109897. PubMed ID: 32505909
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge.
    Carnero Contentti E; Correa J
    Mult Scler Relat Disord; 2020 Jun; 41():102097. PubMed ID: 32278860
    [No Abstract]   [Full Text] [Related]  

  • 13. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.
    Miao Y; Fan L; Li JY
    Front Immunol; 2020; 11():1445. PubMed ID: 32612616
    [No Abstract]   [Full Text] [Related]  

  • 14. COVID-19 and Hypercoagulability.
    Sholzberg M
    Clin Adv Hematol Oncol; 2020 Jul; 18(7):386-389. PubMed ID: 32903249
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19.
    Moutsopoulos HM
    Ann Rheum Dis; 2020 Sep; 79(9):1253-1254. PubMed ID: 32345616
    [No Abstract]   [Full Text] [Related]  

  • 16. How does COVID-19 kill? Uncertainty is hampering doctors' ability to choose treatments.
    Ledford H
    Nature; 2020 Apr; 580(7803):311-312. PubMed ID: 32273618
    [No Abstract]   [Full Text] [Related]  

  • 17. Treating COVID-19 with colchicine in community healthcare setting.
    Della-Torre E; Della-Torre F; Kusanovic M; Scotti R; Ramirez GA; Dagna L; Tresoldi M
    Clin Immunol; 2020 Aug; 217():108490. PubMed ID: 32492478
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial.
    León López R; Fernández SC; Limia Pérez L; Romero Palacios A; Fernández-Roldán MC; Aguilar Alonso E; Pérez Camacho I; Rodriguez-Baño J; Merchante N; Olalla J; Esteban-Moreno MÁ; Santos M; Luque-Pineda A; Torre-Cisneros J
    BMJ Open; 2020 Nov; 10(11):e039951. PubMed ID: 33191263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
    Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
    Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
    Omarjee L; Janin A; Perrot F; Laviolle B; Meilhac O; Mahe G
    Clin Immunol; 2020 Jul; 216():108464. PubMed ID: 32405269
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.